Investors were excited about the company's positive results from a COVID-19 clinical study
News & Analysis: Eiger BioPharmaceuticals
The company reported disappointing news from a clinical study targeting COVID-19 outpatients.
Celladon Corp. and Exelixis Inc. are two speculative biotech stocks that might be worth their substantial risks.
Celladon Corporation shares fell ahead of important trial data that is expected in April.
Celladon Corp. is nearing a make or break moment in its history with the release of its CUPID-2 top-line data for the cardiovascular gene therapy Mydicar. Here's why this speculative biotech is worth a deeper look by risk-tolerant investors.
After 20 years of painstaking work, a game-changing cardiovascular treatment could soon be on hand, potentially richly rewarding early investors. Here's what you need to know.
Motley Fool contributors offer up three potential acquisition targets for Pfizer.
Clinical-stage biotechs tend to bubble to the top of the list of best performing healthcare stocks. Here are three names to watch in 2015 and beyond.
Billionaires took out huge positions in AbbVie, Celladon Corp., and Kite Pharma in the third quarter. Should you follow in their giant footsteps?
Celladon shareholders don't skip a beat by welcoming a favorable designation for Mydicar.